NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate16-11-2021
16-11-2021
Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate16-11-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter ended September 30, 202115-11-2021
Earnings Call for Q2FY22 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.12-11-2021
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
copy of news paper publications12-11-2021
Natco Pharma Q2 net profit drops 68% to Rs 65 crore
The Hyderabad-based firm had posted a consolidated net profit of Rs 203.9 crore in the July-September quarter of the previous fiscal.11-11-2021
Natco Pharma Ltd - 524816 - Record Date Fixed As 24/11/2021 For 2Nd Interim Dividend
Record date fixed as 24/11/2021 for 2nd Interim Dividend11-11-2021
Q2FY22 Quarterly Result Announced for Natco Pharma Ltd.
Highlights: NATCO records INR 415.2 Crore consolidated revenue and INR 65.1 Crore of profit after tax, for the Second Quarter, FY2021-22. NATCO Pharma has recorded consolidated total revenue of INR 415.2 Crore for the Second quarter ended on 30th September, 2021, as against INR 827.90 Crore for the same period last year. The net profit for the period, on a consolidated basis, was INR 65.1 Crores as against INR 203.90 Crore same period last year. The decline in revenue and profits compared to last year quarter is primarily due to a one-off contribution in prior period earnings. The company is poised for growth during latter half of this financial year and confident of a strong rebound in business. During this quarter, Lenalidomide product in Canada and Everolimus higher strength product in USA were launched. The revenues from these products will be realized in immediate quarters. The company is well prepared for its major launch of Lenalidomide in USA during Q4 of this financial year. Result PDF11-11-2021
Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome
Unaudited Financial Results for the quarter and half year ended 30th September, 202111-11-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 FY22 Earnings Call Friday, November 12, 2021 11:00am IST09-11-2021